Page 13 - Oncocyte News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncocyte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncocyte Today - Breaking & Trending Today

OncoCyte Co. (NASDAQ:OCX) Sees Significant Growth in Short Interest

OncoCyte Co. (NASDAQ:OCX – Get Rating) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 1,420,000 shares, an increase of 22.4% from the May 15th total of 1,160,000 shares. Based on an average daily trading volume, of 531,600 shares, the days-to-cover ratio is […] ....

United Kingdom , Needham Company , Pura Vida Investments Llc , Oncocyte Company Profile , Raymond James Financial Services Advisors Inc , Balyasny Asset Management , Oncocyte Co , Cubist Systematic Strategies , Oncocyte Corp , Get Rating , Pura Vida Investments , Broadwood Partners , Systematic Strategies , James Financial Services Advisors , Asset Management , Oncocyte Daily , Nasdaq Ocx ,

StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a report published on Sunday morning. The firm issued a sell rating on the stock. Separately, Needham & Company LLC dropped their target price on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a report […] ....

Oncocyte Company Profile , Vanguard Group Inc , Pura Vida Investments Llc , Needham Company , Goldman Sachs Group Inc , Defender Capital , Oncocyte Corp , Millennium Management , Balyasny Asset Management , Get Rating , Broadwood Partners , Pura Vida Investments , Sachs Group , Asset Management , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a report released on Friday. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC decreased their target price on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a research report […] ....

Oncocyte Corp , Cubist Systematic Strategies , Balyasny Asset Management , Raymond James Financial Services Advisors Inc , Pura Vida Investments Llc , Needham Company , Securities Exchange Commission , Get Rating , Pura Vida Investments , Exchange Commission , Broadwood Partners , James Financial Services Advisors , Systematic Strategies , Asset Management , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NYSE:OCX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NYSE:OCX – Get Rating) in a research note published on Friday. The firm issued a sell rating on the stock. OncoCyte Stock Down 2.1 % OCX opened at $0.22 on Friday. OncoCyte has a fifty-two week low of $0.20 and a fifty-two week high of $1.35. OncoCyte (NYSE:OCX […] ....

Oncocyte Corp , Oncocyte Company Profile , Get Rating , Cyte Stock Down , Oncocyte Daily , Nyse Ocx , Health Technology , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a report published on Friday. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC cut their price objective on OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a report on Tuesday, April […] ....

Goldman Sachs Group Inc , Cubist Systematic Strategies , Raymond James Financial Services Advisors Inc , Oncocyte Corp , Securities Exchange Commission , Needham Company , Pura Vida Investments Llc , Get Rating , Pura Vida Investments , Exchange Commission , Broadwood Partners , James Financial Services Advisors , Sachs Group , Systematic Strategies , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,